AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race
A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.
Pharma & Biotech
Pharma & Biotech
Could BioCardia, Inc.’s integrated platform overcome variability in cardiac regenerative treatments
Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.
Pharma & Biotech
Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?
ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.
Medical Devices & Diagnostics
TytoCare just opened a new FDA category. Can AI make home ear exams clinically useful?
Home diagnostics need regulatory trust. TytoCare’s FDA De Novo win tests whether AI can move ear exams beyond video visits.
Pharma & Biotech
How Apotex’s generic Infuvite pediatric approval could shift the sterile injectable multivitamin market
Pediatric nutrition needs reliable sterile supply. Apotex’s Infuvite generic approval tests whether complex generics can ease that gap.
Pharma & Biotech
Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability
Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.
Features & Analysis
Why BrioHealth’s Brio4Kids trial could become a test case for pediatric LVAD innovation
BrioHealth Solutions has received United States Food and Drug Administration conditional approval to initiate the Brio4Kids Trial, a pediatric clinical evaluation of the BrioVAD System in children with advanced heart failure. The trial will proceed under the existing Investigational Device Exemption for the INNOVATE Trial, giving the medical device developer a defined pathway to test
Pharma & Biotech
Why Humacyte, Inc.’s vascular tissue platform is gaining attention in high-risk dialysis populations
Why Humacyte, Inc.’s ATEV is gaining traction in dialysis care. Explore clinical data, risks, and what comes next in vascular access innovation.
Pharma & Biotech
What ZORYVE cream’s infant indication means for non-steroidal eczema treatments
Can ZORYVE cream transform infant eczema care? Explore what this FDA filing means for non-steroidal treatment strategies today.
Pharma & Biotech
Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.